LIXIL-JS-FOUNDATION
27.7.2016 07:14:00 CEST | Business Wire | Press release
The LIXIL JS Foundation (located in Koto-ku, Tokyo; Chairperson: Yoko Ushioda), which facilitates surveys and research related to the housing and building materials industries as well as supporting the development of human resources, conducted the Open Final Screening for the 6th LIXIL International Student Architectural Competition at the Keidanren Kaikan (Chiyoda-ku, Tokyo) on July 20, 2016 (Wed). The purpose of the competition is to seek and review next-generation sustainable housing technology and communicate that technology to the global society. The top three universities chosen from twelve participating universities in ten countries gave presentations, and INFINITE FIELD by Royal Danish Academy of Fine Arts (Denmark) was selected as the winner.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160726006668/en/
During the Open Final Screening, a heated discussion occurred between the head of jury, Kengo Kuma (Architect/ Professor, the University of Tokyo) and jurors, Tomonari Yashiro (Professor, Institute of Industrial Science, the University of Tokyo/ Vice President, the University of Tokyo), Masato Araya (Structural Designer/ Professor Emeritus, Waseda University), Yoshiharu Tsukamoto (Architect/ Co-founder of Atelier Bow-Wow/ Professor, Graduate school of Tokyo Institute of Technology) and Dana Buntrock (Architect, Department of Architecture, University of California, Berkeley). The theme of the 6th competition was “Comfort and Lightness.” As the competition’s first attempt, the contestants proposed a light shelter, which can be easily assembled and moved. This time around, as another first attempt, their mockups were actually brought in and exhibited at the hall for the final screening.
Royal Danish Academy of Fine Arts’ INFINITE FIELD was highly rated in various aspects, including a whole new architectural approach that can safely be referred to as an extension of “furniture” that gives consideration even to the form created by the human body and wood, a high degree of perfection of details, including materials to be cut and assembled, and a 360 degree open design that can become a big appeal when installed in Taiki-cho, Hokkaido.
In his general comments, the head juror, Kengo Kuma said, “Screening by using mockups was something innovative that I had never experienced and it gave the students a good opportunity to think about architecture starting with materials. Moreover, this competition was valuable also from a perspective of architectural culture in that their work remains.” At the award ceremony, Mr. Konstatinos Fetsis of Royal Danish Academy of Fine Arts commented, “I am very pleased to have been able to take part in this competition and this journey with these members. This has become such a wonderful experience that I will never forget as a student who majors in architecture.”
With support from Kengo Kuma & Associates, the team will arrive at a final design for “INFINITE FIELD,” and the project is scheduled to be built in October 2016 on a site at Memu Meadows, located in Taiki-cho, Hokkaido.
[Reference Information]
List of Winning Works
-
Top Prize
INFINITE FIELD by Royal Danish Academy
of Fine Arts
- Award of Excellence (2 works)
LEVITATING
ATMOSPHERES by HESAM University / ENSA Paris-La-Villette
Light Skin
HOUSE by Yokohama National University
6th LIXIL International Student Architectural Competition
Theme:
Comfort and Lightness
The contemporary concept of comfort
hinges on blocking out the environment and creating barriers. But
perhaps what we really need today is to live in closer proximity to
nature. Please design a light shelter, one which can be easily assembled
and moved, and also allows residents to enjoy a comfortable life. The
ability to move the house means interpreting, considering, and creating
a relationship with its surroundings. And the ability to easily assemble
means it can become linked with the natural environment and ground, and
draw out the richness of the place. Please devise a house that can be
easily assembled and moved, and will allow the residents to enjoy the
environment, both the summer and winter in Taiki-cho, Hokkaido. The
relationship with nature and the surrounding area in your proposal might
also include a method of interpreting the environment if the house was
relocated to a city.
1. Participating universities:
12 universities in 10 countries
*
The three universities marked with X proceeded to the Open Final
Screening held on July 20, 2016.
| Cornell University (USA) | ||
| Parsons School of Design (USA) | ||
| Universidad Nacional Autónoma de México (México) | ||
|
X |
Royal Danish Academy of Fine Arts (Denmark) |
|
| Polytechnic of Milan (Italy) | ||
|
X |
HESAM University / ENSA Paris-La-Villette (France) |
|
| Swiss Federal Institute of Technology (ETH) Zurich (Switzerland) | ||
| University of Melbourne (Australia) | ||
| Chulalongkorn University (Thailand) | ||
| University of Cape Town (South Africa) | ||
| Kyoto Institute of Technology (Japan) | ||
|
X |
Yokohama National University (Japan) |
|
2. Judging method
Twelve universities in ten countries were
invited to submit proposals for a next-generation, sustainable house
designed for a cold region. Three entrants were then selected in the
first screening (based on documents submitted). The top prize winner was
subsequently chosen in the Open Final Screening.
3. Jury:
Kengo Kuma (Professor at the Graduate School of
Architecture, The University of Tokyo)
Tomonari Yashiro (Deputy
Director and Professor at the Institute of Industrial Science, The
University of Tokyo)
Masato Araya (Structural Engineer, Professor
Emeritus at Waseda University)
Yoshiharu Tsukamoto (Professor at
Tokyo Institute of Technology, Co-Principal of Atelier Bow-Wow)
Dana
Buntrock (Professor at Department of Architecture, University of
California, Berkeley)
4. Prizes
Top prize (one work): $15,000 (USD; including
design fee)
Award of Excellence (two works): $3,000
*The winner’s work “INFINITE FIELD” will be built on a site at Memu Meadows, located in Taiki-cho, Hokkaido (to be completed in October 2016).
View source version on businesswire.com: http://www.businesswire.com/news/home/20160726006668/en/
Contact:
LIXIL JS Foundation
Kumeo Takahata, +81(0)3-5626-1008
2-1-1,
Oshima, Koto-ku, Tokyo 136-8535
LIXIL JS Foundation website: http://www.lixiljsfound.com/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
